LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation’s (NASDAQ:CYTR) majority-owned subsidiary, Worcester, Massachusetts-based RXi Pharmaceuticals Corporation (RXi), today announced formation of a five-member Board of Directors with RNA interference (RNAi), biopharmaceutical, corporate governance, finance and legal expertise. RXi is a biopharmaceutical research and development company that will focus on developing RNAi-based therapeutics for the treatment of human disease.
